報價延遲最少15分鐘:2026/10/20 22:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.41/0.50
|
|
企業價值
33.18M
|
| 資產負債 |
|
每股賬面淨值
0.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics. |
